There has been, understandably, much attention paid to school shootings by students and carjackings by young teens as far as public interest is concerned. The facts, however, show a general decline in youth arrests over the past three decades. Nevertheless, the uptick in public perception of juvenile crime presents an opportunity to create what could be a better deterrence method than the currently favored law enforcement approach: better health strategies.
Preventing child maltreatment can result in a reduction in suicide and mental disorders, research has found. The link between childhood maltreatment and adult depression has been known for some time, but the first study published has shown that this maltreatment causes mental disorders and suicide. The study took into account genetic and environmental confounding. For the study, maltreatment was defined as physical abuse, sexual abuse, emotional, or neglect before or at the age of 18.
A new document from the National Association of State Alcohol and Drug Abuse Directors (NASADAD) and the National Council for Mental Wellbeing released last month highlights the best practices for treatment of adolescent substance use disorders (SUDs). Replete with many links, the document will help not only treatment providers but also policymakers, schools, and more. The document is researched and footnoted.
Fluvoxamine Maleate (generic) — Luvox, Luvox CR (brand)
Researchers have found that abstinence-based policies in sober living homes should include a ban on cannabis use as well as alcohol and other drug use. The study was meant to look more closely at the evidence suggesting that cannabis may be “safer” than other drugs. However, cannabis legalization has put sober homes in a difficult position regarding cannabis use among residents.
The Food and Drug Administration (FDA) did not accept the application of Lykos Therapeutics for MDMA as a treatment for post-traumatic stress disorder (PTSD). In a letter dated Aug. 9 and released by Lykos Therapeutics, the for-profit arm of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company stated that it is disappointed in the FDA response, but that it intends to pursue the goal of approval. This announcement was followed by the retraction of three peer-reviewed studies on Aug. 9 as well. The FDA did not completely reject the idea of ever approving MDMA, but asked Lykos for more information.
This is a literature review that ended in 2021, so on the bright side, you could say things have changed. But lack of institutional support was the main reason for physician reluctance to treat addiction, based on a large-scale review published in JAMA Network Open in July 2024.
While it's tempting to let drug users — including young adults and adolescents — use in solitude (out of sight, in other words), bear in mind one thing: as unpleasant as it sounds, having naloxone on hand and knowing your teen is using drugs can save his or her life, if someone is there when the drug is administered.
Divalproex sodium delayed release, Depakote, Depakote Sprinkle capsules, Divalproex sodium extended release, Depakote ER, Depakene, Valproic acid* (generic) — Valproate (brand)
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：